Immunogenic targets for melanoma
AssigneeAventis Pasteur Limited
InventorsPeter Emtage, Liza Karunakaran, Artur Pedyczak, Brian Barber
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.
Claims38
An expression vector comprising at least one nucleic acid sequence selected from the group consisting of 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, 50, 51, 52, and 53.
The expression vector of claim 22 wherein the vector is a plasmid or a viral vector.
The expression vector of claim 23 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
The expression vector of claim 24 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
A composition comprising an expression vector in a pharmaceutically acceptable carrier, said vector comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, and 53.
A method for preventing or treating cancer comprising administering to a host an expression vector comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO:
- 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, and 53.
A peptide selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26.
A composition comprising peptide selected from the group consisting of SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 in a pharmaceutically acceptable carrier.
A method for preventing or treating cancer comprising administering to a peptide selected from the group consisting of SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26.
Dependencies are inferred from the claim text.